GlassScriptPhysician profile
Carissa Pardekooper
NPI 1063815017
$1,307.73
in general payments reported to CMS, 2019-2025
15 companies · $967 in 2025
The $967 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.97 · 2022: $146 · 2023: $168 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.84 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.64 | 2022-2025 | |
| Genzyme Corporation | $226.90 | 2025 | |
| Janssen Scientific Affairs, LLC | $124.93 | 2022 | |
| Sun Pharmaceutical Industries INC. | $93.57 | 2025 | |
| Arcutis Biotherapeutics, INC. | $87.36 | 2025 | Zoryve |
| Janssen Biotech, INC. | $64.95 | 2023 | Tremfya |
| Kerecis Limited | $51.74 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Amgen INC. | $45.22 | 2025 | Otezla |
| Galderma Laboratories, L.P. | $39.33 | 2025 | Nemluvio |
| Pfizer INC. | $34.29 | 2025 | |
| Lilly USA, LLC | $30.16 | 2021-2025 | Ebglyss, Taltz |
| Incyte Corporation | $29.82 | 2025 | Opzelura |
| Biofrontera INC. | $14.25 | 2025 | |
| Ucb, INC. | $13.54 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carissa Pardekooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.